Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.20 Consensus PT from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $25.20.

ATXS has been the subject of several research analyst reports. TD Cowen assumed coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a “buy” rating and a $35.00 price objective for the company. Oppenheimer raised their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 14th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. AJOVista LLC acquired a new stake in shares of Astria Therapeutics during the 4th quarter worth about $51,000. Vivo Capital LLC grew its stake in Astria Therapeutics by 47.7% in the 4th quarter. Vivo Capital LLC now owns 2,482,727 shares of the biotechnology company’s stock worth $19,067,000 after acquiring an additional 801,528 shares during the period. Panagora Asset Management Inc. purchased a new stake in Astria Therapeutics in the 4th quarter worth approximately $119,000. Trexquant Investment LP acquired a new position in Astria Therapeutics in the 4th quarter valued at $409,000. Finally, Affinity Asset Advisors LLC lifted its stake in shares of Astria Therapeutics by 46.6% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,466,465 shares of the biotechnology company’s stock worth $11,262,000 after purchasing an additional 466,165 shares during the period. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Stock Up 1.0 %

Shares of ATXS opened at $11.18 on Friday. Astria Therapeutics has a 52-week low of $4.26 and a 52-week high of $16.90. The company has a 50-day simple moving average of $10.17 and a 200-day simple moving average of $11.34. The company has a market capitalization of $613.93 million, a PE ratio of -4.82 and a beta of 0.73.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). On average, research analysts anticipate that Astria Therapeutics will post -1.62 EPS for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.